{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:12:37Z","timestamp":1785251557096,"version":"3.55.0"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T00:00:00Z","timestamp":1580256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0224875","type":"journal-article","created":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T13:35:11Z","timestamp":1580304911000},"page":"e0224875","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["HIV\/HCV therapy with ledipasvir\/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens"],"prefix":"10.1371","volume":"15","author":[{"given":"Gregory D.","family":"Huhn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moti","family":"Ramgopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamta K.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Hinestrosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0916-7950","authenticated-orcid":true,"given":"David M.","family":"Asmuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihad","family":"Slim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shauna","family":"Applin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie H.","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuping","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moupali","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thai","family":"Nguyen-Cleary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Piontkowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bill","family":"Guyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Rossaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9435-2386","authenticated-orcid":true,"given":"Richard H.","family":"Haubrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,1,29]]},"reference":[{"issue":"2","key":"pone.0224875.ref001","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","author":"European Association for the Study of the Liver","year":"2018","journal-title":"J Hepatol"},{"key":"pone.0224875.ref002","unstructured":"The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. HCV guidance: Recommendations for testing, managing, and treating hepatitis C. Available from: https:\/\/www.hcvguidelines.org\/sites\/default\/files\/full-guidance-pdf\/HCVGuidance_May_24_2018b.pdf Cited 7 March 2019."},{"key":"pone.0224875.ref003","unstructured":"European AIDS Clinical Society. EACS Guidelines version 9.0 October 2017. Available from: http:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines\/eacs-guidelines.html Cited 7 March 2019."},{"key":"pone.0224875.ref004","article-title":"Hepatitis C eradication: who is being left behind in the HIV population?","author":"MK Jain","year":"2018","journal-title":"IDWeek"},{"issue":"6","key":"pone.0224875.ref005","doi-asserted-by":"crossref","first-page":"S-1189","DOI":"10.1016\/S0016-5085(18)33931-3","article-title":"Untreated HCV in HIV\/HCV co-infection; data from the Trio Network","volume":"154","author":"D Jayaweera","year":"2018","journal-title":"Gastroenterology"},{"issue":"4","key":"pone.0224875.ref006","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.3748\/wjg.v22.i4.1421","article-title":"New approaches in the treatment of hepatitis C","volume":"22","author":"R Gonzalez-Grande","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"16","key":"pone.0224875.ref007","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"N Afdhal","year":"2014","journal-title":"N Engl J Med"},{"issue":"20","key":"pone.0224875.ref008","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"N Afdhal","year":"2014","journal-title":"N Engl J Med"},{"issue":"20","key":"pone.0224875.ref009","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"KV Kowdley","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"pone.0224875.ref010","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa1501315","article-title":"Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1","volume":"373","author":"S Naggie","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"pone.0224875.ref011","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/jvh.12554","article-title":"Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus","volume":"23","author":"ZM Younossi","year":"2016","journal-title":"J Viral Hepat"},{"key":"pone.0224875.ref012","unstructured":"Bhagani S, Sulkowski M, Cooper C, Kwo P, Kowdley K, Naik S, et al. Ledipasvir\/sofosbuvir is safe and effective for the treatment of patients with genotype 1 chronic HCV infection in both HCV mono- and HIV\/HCV coinfected patients. 15th European AIDS Conference; 21\u201324 October; Barcelona, Spain2015. p. Abstract 386."},{"issue":"5","key":"pone.0224875.ref013","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/hep.29308","article-title":"High hepatitis C cure rates among black and nonblack human immunodeficiency virus-infected adults in an urban center","volume":"66","author":"O Falade-Nwulia","year":"2017","journal-title":"Hepatology"},{"issue":"2","key":"pone.0224875.ref014","doi-asserted-by":"crossref","first-page":"ofx062","DOI":"10.1093\/ofid\/ofx062","article-title":"Highly successful hepatitis C virus (HCV) treatment outcomes in human immunodeficiency virus\/HCV-coinfected patients at a large, urban, Ryan White Clinic","volume":"4","author":"M Patel","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"pone.0224875.ref015","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/cid\/cix111","article-title":"Effectiveness of all-oral antiviral regimens in 996 human immunodeficiency virus\/hepatitis C virus genotype 1-coinfected patients treated in routine practice","volume":"64","author":"D Bhattacharya","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"9","key":"pone.0224875.ref016","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1093\/jac\/dkw203","article-title":"High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV\/HCV-coinfected patients: a real-world perspective","volume":"71","author":"C Hawkins","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"pone.0224875.ref017","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/hiv.12429","article-title":"Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV\/HIV-coinfected patients: real-life safety and efficacy","volume":"18","author":"L Milazzo","year":"2017","journal-title":"HIV Med"},{"issue":"3","key":"pone.0224875.ref018","doi-asserted-by":"crossref","first-page":"234","DOI":"10.14218\/JCTH.2016.00026","article-title":"HIV\/HCV antiviral drug interactions in the era of direct-acting antivirals","volume":"4","author":"DP Rice","year":"2016","journal-title":"J Clin Transl Hepatol"},{"key":"pone.0224875.ref019","unstructured":"Department of Health and Human Services. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Available from: http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf Cited 7 March 2019."},{"issue":"9987","key":"pone.0224875.ref020","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials","volume":"385","author":"PE Sax","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"pone.0224875.ref021","doi-asserted-by":"crossref","first-page":"e00353","DOI":"10.1002\/prp2.353","article-title":"Lack of clinically important PK interaction between coformulated ledipasvir\/sofosbuvir and rilpivirine\/emtricitabine\/tenofovir alafenamide","volume":"5","author":"JM Custodio","year":"2017","journal-title":"Pharmacol Res Perspect"},{"key":"pone.0224875.ref022","unstructured":"Garrison KL, Custodio JM, Pang PS, Das M, Cheng F, Ma G, et al. Drug interactions between anti-HCV antivirals ledipasvir\/sofosbuvir and integrase strand transfer inhibitor-based regimens. Presented at: 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy; May 26\u201328, 2015; Washington, DC, USA."},{"issue":"6","key":"pone.0224875.ref023","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40265-015-0381-2","article-title":"Ledipasvir\/Sofosbuvir: a review of its use in chronic hepatitis C","volume":"75","author":"GM Keating","year":"2015","journal-title":"Drugs"},{"issue":"2","key":"pone.0224875.ref024","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.2016.8900","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society-USA Panel","volume":"316","author":"HF Gunthard","year":"2016","journal-title":"JAMA"},{"key":"pone.0224875.ref025","unstructured":"Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV 2017. Available from: https:\/\/aidsinfo.nih.gov\/guidelines Cited 7 March 2019."},{"issue":"4","key":"pone.0224875.ref026","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1016\/S2352-3018(16)00024-2","article-title":"Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial","volume":"3","author":"JE Gallant","year":"2016","journal-title":"Lancet HIV"},{"issue":"1","key":"pone.0224875.ref027","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(15)00348-5","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study","volume":"16","author":"A Mills","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"pone.0224875.ref028","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/QAI.0000000000001186","article-title":"Brief report: Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected adults with renal impairment: 96-week results from a single-arm, multicenter, open-label phase 3 study","volume":"74","author":"FA Post","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"pone.0224875.ref029","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/QAI.0000000000001344","article-title":"Brief report: Long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-infected, virologically suppressed adults","volume":"75","author":"F Raffi","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"pone.0224875.ref030","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S2352-3018(17)30032-2","article-title":"Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study","volume":"4","author":"E DeJesus","year":"2017","journal-title":"Lancet HIV"},{"issue":"5","key":"pone.0224875.ref031","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1016\/S2352-3018(17)30031-0","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study","volume":"4","author":"C Orkin","year":"2017","journal-title":"Lancet HIV"},{"issue":"2","key":"pone.0224875.ref032","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/QAD.0000000000000903","article-title":"Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir","volume":"30","author":"K Townsend","year":"2016","journal-title":"AIDS"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0224875","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T13:35:36Z","timestamp":1580304936000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0224875"}},"subtitle":[],"editor":[{"given":"Jee-Fu","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,1,29]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0224875","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,29]]}}}